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Definition of a pharmacy
Pharmacy is a dynamic, information driven, patient-orientated 
profession whereby the pharmacist, through his competence and 










outcome of therapy and by being actively involved in the design, 
implementation and monitoring of pharmaceutical plans 
•	 Provider	of	cost-effective	and	efficient	pharmaceutical	services	
Diabetes and disease state management (DSM)
Type 2 diabetes is an escalating epidemic with predictions of 
worldwide prevalence exceeding three million by 2030.1 There 
is now irrefutable evidence that strict control of type 2 diabetes 
can delay the onset of the complications of this disease,2 is cost-
effective, and brings about improvements in overall quality of life.3,4 
These	 findings	 highlight	 the	 need	 for	 disease	 state	 management	
(DSM) approaches which focus on intensive management of type 
2 diabetes involving regular monitoring, follow-up, and continuity of 
care. Such approaches have been shown to be effective in improving 
disease control in a recent meta-analysis of disease management 
programmes.5
The majority costs of diabetes are associated with the possible 
complications of the disease including amputations, blindness, 
cardiovascular conditions, stroke, and renal disease. In patients with 
diabetes, cost of therapy, severity of disease, presence of co-morbid 
conditions and complexity of drug regimen have all been shown to 
be factors associated with medication adherence.6,7–9 
Pharmacists and their role in DSM
Community pharmacies have an important role to play in DSM.10–15 
In addition to dispensing prescription medications, their involvement 
shows	 beneficial	 effects	 in	 patient	 education	 and	 disease	
management.16,17 Community pharmacies are ideally placed to 
contribute to DSM programmes and assist in the detection, education 
and referral of individuals at risk of diabetes.18 They are widely 
accessible, available, in frequent contact with the public and able to 
access people who are apparently healthy. DSM in both clinics18–22 
and community pharmacy settings23–27 are highly effective and a high 
proportion of consumers currently support pharmacist provision of 









for the presence of diabetic complications, for example, eye and 
feet examinations or drug therapy management. 
•	 A	new	role	of	the	pharmacist	(educator)	as	tutor	and	facilitator	
has emerged out of study circles.
A pharmacist is one of few medical professionals in the world to whom a patient or anyone else can go for a consultation or advice without an 
appointment. They are easily accessed and knowledgeable about a myriad of aspects concerning patients and their medication. It is thus of 
the utmost importance to take these skills into consideration when it comes to diabetic education. Pharmacists have long-term relationships 
with most of their chronic patients, which sets a good foundation for mutual trust and respect and better patient compliance.
JEMDSA 2009;14(3):148-150
149
Diabetes Education: The role of a community pharmacist in diabetes education
2009 Volume 14 No 3JEMDSA
Attitudes	 were	 significantly	 more	 positive	 towards	 diabetes	 and	
medication, towards communicating with a pharmacist and patients 
perceptions regarding knowledge about medication among patients 
who had been in contact with a pharmacist.15 Patient satisfaction 
and patient-pharmacist relationships are important because these 
factors typically lead to positive health behaviours, such as improved 
adherence and disease management, subsequently leading to 
improved disease outcomes.12,13
Study Circle (SC)
Another idea for involving the pharmacy in diabetes disease 
management programmes might come from the so-called Study 
Circles (SC).13,14 SC was originally a small group of people interested 
in the same subject: they invited lecturers, did literature searches 
and had discussions in the group. The aim of studies in an SC is 
to gain knowledge that does not only include learning facts about 
the subject, but also enables one to understand and change ones 
existence. An SC for diabetes should be built on this tradition, thus 
a participatory approach to education should be used; knowledge 
should be sought by group members in texts as well as from their 
own experiences. The long-term goal of an SC for diabetes should be 
to develop a diabetes education programme to teach glucose control 
and help participants cope with their diabetes. The pharmacy is a 
good setting since it is a widely distributed service. 
The pharmacist as SC facilitator
It is now well recognised that patients with chronic diseases must 
know how to handle their situation and that the long-term outcomes 
very much depend on how successful they are in their endeavour. 
The group setting promotes learning through peer help and gives 
emotional support to participants. Facilitators should be trained to 
promote learning and be able to handle conflict that might arise 
out of group discussions. For some it can be hard in the beginning 
to abstain from lecturing and let the group do the work and it is 
therefore imperative that some knowledge of group dynamics is 
present. In SC for diabetes, specially trained pharmacists can act as 
facilitators and teach patients how to self-monitor glucose, interpret 
the results and act upon them.13 
The patients can join a study circle for one year and the goal is that 
they should learn to normalise their blood glucose values and have 
the opportunity to discuss psychological reactions following the 
diagnosis. This can be achieved with 10–12 sessions of three hours 








physician is due both by participants to one another and by the 
group leaders13
Effective DSM
The key to effective diabetes management is the adoption of a 
systematic approach of collecting, interpreting, and acting on blood 
glucose data. 
Collecting – Glucose	profiling	has	consistently	been	associated	with	
improved glycaemic control, whether evaluated as part of an intensive 
insulin management strategy or as a component of management of 
patients not treated with insulin.28–30 Intensive insulin therapy guided 
by	SMBG	performed	at	least	four	times	per	day	was	associated	with	
a > 2.0% reduction in HbA1c.28	Similar	findings	were	observed	 in	
patients with type-2 diabetes.29
Interpreting – Traditionally, people with diabetes keep handwritten 
blood	glucose	(BG)	logs.	Although	useful,	and	a	necessary	component	
of diabetes management, logbooks can be incomplete, inaccurate 
and	 illegible,	 which	 may	 lead	 to	 faulty	 analyses	 of	 BG	 trends	
associated with meals, medications and daily activities. The use of 
data-management software may help both patients and health care 
professionals	manage	these	profiles	and	achieve	glycaemic	control.	
Ascensia®‚	 WinGLUCOFACTS®‚ Professional Software from Bayer 
HealthCare was developed to assist in diabetes management by 










software in the real-world management of diabetes.31 To download 
this software free of charge, go to http://software.ascencia.com
Acting – By using a systematic approach based on pre- and post-
meal targets, it is possible to continually evaluate the effectiveness 
of the diabetes management protocol by analysing the blood 
glucose	data	to	assess	for	specific	patterns.32 Blood glucose meter 
downloads may aid in the recognition of these patterns. If certain 
patterns	emerge	(e.g.	significant	postprandial	glycaemic	excursions	
following breakfast) the management plan can be reassessed, and 
appropriate action taken, by both the health care professional and 
the patient.32 The ability of the patient, as well as the health care 
provider, to recognise patterns and implement changes is a critical 
component	of	affecting	positive	outcomes	using	glucose	profiling.
Taken as a whole, clinical evidence strongly suggests that the 
systematic	 use	 of	 glucose	 profiles	 from	 SMBG	 data	 improves	
glycaemic control in patients with diabetes. It is important, however, 
that	SMBG	data	be	accurately	obtained	and	reviewed	so	that	patterns	
of glycaemic variability can be addressed through changes in patient 
management	plans.	Patient	education	regarding	SMBG,	interpretation	
of	glucose	profiles,	and	adjustments	to	the	management	plan	may	
facilitate adherence to appropriate treatment regimens and improve 
outcomes.
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Conclusion
Evidence suggests that strict control over diabetes results in 
improvements in overall quality of life; is cost effective and can 
delay complications. This highlights the need for DSM approaches 
which focuses on intensive management of diabetes involving 
regular monitoring, follow-up and continuity of care. This is an 
area of expertise where the pharmacist can play a profound role. 
Pharmacists are easily accessible and share long-term relations 
with most of their chronic patients, which set a good foundation for 
mutual trust, respect and better patient compliance.
Community pharmacies are ideally situated to contribute to DSM 
programmes and assist in the detection, education and referral 
of individuals at risk of diabetes. Since chronic patients visit their 
pharmacies at least once a month for their follow-up medicine, this 
is the ideal opportunity for a pharmacist to use data- management 
software	to	download	a	diabetic’s	glucometer	and	to	analyse	their	
glucose trends. Following this, the pharmacist can give advice and 
educate	the	patient	to	manage	his	condition	more	efficiently.
Another plan of action where a pharmacist can get involved with DSM 
programmes is to make use of SC. The goals of SC are to organise 
training sessions in diabetes management and care for people of all 
ages with the disease in order to promote independence, equity and 
self-sufficiency.	SC	held	at	pharmacies	is	a	feasible	way	of	educating	
persons with diabetes. The role of the group leader (in this case a 
pharmacist) is to promote learning through active participation rather 
than to force a lot of facts. Participants improved their perception of 
diabetes and gained subjective control over their disease. Patients 
gave and received emotional support in the groups which were 
described as a stimulating environment for learning self-care.
Pharmacists could, in fact, play a more active role in quality 
diabetes care. Systematically educated pharmacists could perform 
group education for diabetes patients, thus easing the burden on 
the primary health care centres and giving participants the time 
they need. Mutual respect between medical professionals and 
the	pharmacist	 for	each	other’s	competence	could	 lead	 to	a	well-
functioning system for all parties involved.
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